Eli Lilly Opens Early Access Program for Experimental Obesity Drug Retatrutide

Eli Lilly (LLY) will provide its experimental, next-generation obesity drug, retatrutide, to a limited number of patients through an expanded access program ahead of its potential U.S. Food and Drug Administration (FDA) approval. The initiative is designed for individuals with severe medical needs who are unable to participate in ongoing clinical trials.

Program Details and Eligibility

According to a company spokesperson, the program is intended for patients who meet specific medical criteria and for whom early access is deemed "medically appropriate." The company confirmed it has built the program consistent with FDA guidance and is actively reviewing requests from healthcare providers.

To qualify, patients must meet several strict conditions:

• Be 18 years of age or older.
• Have refractory obesity despite tolerating the highest approved dose of an existing obesity therapy.
• Have at least two serious or life-threatening obesity-related complications under medical care.
• Be unable to participate in an ongoing clinical trial for retatrutide or a comparable investigational treatment.

A New Generation of Treatment

Ad

Retatrutide is a highly anticipated drug that targets three different metabolic hormones: GLP-1, GIP, and glucagon. This triple-agonist mechanism differentiates it from Lilly's current blockbuster obesity treatment, Zepbound, which targets only GLP-1 and GIP.

This novel approach has shown significant promise in clinical trials. In a statement from July, Eli Lilly reported that an 80-week study of adults with severe obesity and heart disease showed an average weight loss of 22.6% for those on the highest weekly dose of retatrutide.

Market Context and Next Steps

The decision to offer pre-approval access, first reported by STAT News, highlights the significant demand for new options in the rapidly expanding weight-loss drug market. It allows the company to provide a potential treatment for the most severe cases while it proceeds with the formal regulatory process.

Eli Lilly plans to file for FDA approval for retatrutide in the first quarter of next year. A successful launch would further solidify the company's dominant position in the lucrative market for metabolic and obesity therapies.